Summit Therapeutics Reports Financial Results for the Third Quarter Ended 31 October 2016 and Operational Progress
December 15, 2016 07:00 ET
|
Summit Therapeutics PLC
OXFORD, United Kingdom, Dec. 15, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular...
Summit Enrols Patients in the United States Into PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Patients With DMD
November 16, 2016 07:00 ET
|
Summit Therapeutics PLC
OXFORD, United Kingdom, Nov. 16, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...
Summit Therapeutics Presents Preclinical DMD Data at the 21st International Congress of the World Muscle Society
October 06, 2016 07:00 ET
|
Summit Therapeutics PLC
Summit reports on development of new, automated biomarker tools to evaluate disease status of muscle biopsies OXFORD, United Kingdom, Oct. 06, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc...
Summit to Host Conference Call to Discuss Exclusive License and Collaboration Agreement With Sarepta Therapeutics for European Rights to Summit’s Utrophin Modulator Pipeline for the Treatment of Duchenne Muscular Dystrophy
October 04, 2016 07:01 ET
|
Summit Therapeutics PLC
OXFORD, United Kingdom, Oct. 04, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...
Sarepta Therapeutics and Summit Enter Into Exclusive License and Collaboration Agreement for European Rights to Summit’s Utrophin Modulator Pipeline for the Treatment of Duchenne Muscular Dystrophy
October 04, 2016 07:00 ET
|
Summit Therapeutics PLC; Sarepta Therapeutics
Sarepta and Summit collaborate to advance the development of novel therapies for patients with Duchenne muscular dystrophySummit receives $40 million upfront, with potential future ezutromid-related...
Summit Receives Rare Pediatric Disease Designation From US FDA for Ezutromid in Treatment of Duchenne Muscular Dystrophy
September 27, 2016 07:00 ET
|
Summit Therapeutics PLC
OXFORD, United Kingdom, Sept. 27, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...
Summit Launches Online Resource on Utrophin Modulation for the Duchenne Muscular Dystrophy Community
September 12, 2016 07:00 ET
|
Summit Therapeutics PLC
OXFORD, United Kingdom, Sept. 12, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...
FDA allows Phrixus’s IND for Carmeseal-MD™ (P-188 NF) in Duchenne muscular dystrophy (DMD)
September 07, 2016 08:00 ET
|
Phrixus Pharmaceuticals, Inc.
ANN ARBOR, Mich., Sept. 07, 2016 (GLOBE NEWSWIRE) -- Phrixus Pharmaceuticals is announcing that FDA allowed Phrixus’s IND for Carmeseal-MD (P-188 NF) in Duchenne muscular dystrophy (DMD). The...
Summit Reports Positive Phase 1 New Formulation Data and Outlines Route to Market Strategy for DMD Candidate Ezutromid
August 09, 2016 07:00 ET
|
Summit Therapeutics PLC
New formulation of ezutromid achieved over a six-fold increase in maximum plasma levels in patientsPlans include incorporating new formulation into PhaseOut DMD trial OXFORD, United Kingdom, Aug. 09,...
First Patient Enrolled in Summit’s PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Boys With DMD
June 17, 2016 07:00 ET
|
Summit Therapeutics PLC
OXFORD, United Kingdom, June 17, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...